Kineta Inc. (KA) Stock
KA is no longer traded. Kineta was delisted from the Nasdaq in November 2024.
Prices on this page are historical; the last trade was November 20, 2024 at $0.48.
Kineta stock price history
KA final trading statistics
- Final close
- $0.48
- Final trading day
- Nov 20, 2024
- Market cap at delisting
- $5.89M
- Shares outstanding
- 12.26M
- Final 52-week range
- $0.33 – $4.77
- Avg. volume (final 3 mo.)
- 56,399
- All-time high (split-adj.)
- $2814.00 · Jun 2016
- All-time low (split-adj.)
- $0.34 · Apr 2024
- Return since IPO
- -99.9%
- Beta
- —
- Book value / share
- -$0.66
- Price / book
- -0.72
Kineta annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2023 | $5.44M | -$14.1M | -$1.50 |
| FY2022 | $1.95M | -$63.1M | -$24.35 |
| FY2021 | $9.09M | -$12.0M | -$26.95 |
| FY2020 | $10.49M | -$13.9M | -$38.08 |
| FY2019 | $5.00M | -$59.1M | -$161.00 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About Kineta Inc.
Kineta, Inc. is a clinical-stage biotechnology company with a focus on developing immunotherapies that transform patients' lives. It focuses on developing potentially differentiated immunotherapies that address the challenges with current cancer therapy. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors, including non-small cell lung, ovarian, renal cell carcinoma, head and neck, renal cell, and colorectal cancers. It is also developing anti-CD27 agonist mAb immunotherapy to address the problem of exhausted T cells. The company has collaboration and license agreements with MSD International Business GmbH, Genentech, Inc., FAIR Therapeutics B.V., and GigaGen, Inc. Kineta, Inc. is headquartered in Seattle, Washington.
Kineta stock FAQ
What happened to Kineta stock?
Kineta stock was delisted from the Nasdaq. Its final close was $0.48 on November 20, 2024.
Is KA stock still trading?
No. KA was delisted from the Nasdaq in November 2024 and no longer trades on a U.S. exchange.
What was the last price of KA stock?
KA closed at $0.48 on its final trading day, November 20, 2024, for a market value of about $5.89M.
What were Kineta's revenue and earnings in its last full fiscal year?
Kineta reported revenue of $5.44M and net income of -$14.1M in fiscal 2023, its last full year as a public company.
When did Kineta go public?
Kineta Inc. stock began trading on February 11, 2016.